PriceSmart Announces Change to Previously Scheduled Conference Call
Prnewswire· 2025-06-27 20:00
SAN DIEGO, June 27, 2025 /PRNewswire/ -- PriceSmart, Inc. (the "Company") (NASDAQ: PSMT) today announced that it will hold its conference call related to its financial results for the third quarter of fiscal year 2025 on Monday, July 14, 2025, rather than Friday, July 11, 2025 as previously announced due to a scheduling conflict. The call will be held at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) on Monday, July 14. Individuals interested in participating in the conference call may do so by dialing to ...
Update: MMA.INC Announces Blockchain and AI-Driven Crypto Platform through Strategic Web3 Alliance with Morphotech to Reward Martial Arts Fans with Crypto Tokens for Engagement and Participation
Globenewswire· 2025-06-27 20:00
New York, NY, June 27, 2025 (GLOBE NEWSWIRE) -- Mixed Martial Arts Group Limited (NYSE American: MMA) (“MMA” or the “Company”), an NYSE American listed innovator at the intersection of combat sports and digital transformation, aims to spark a global movement to redefine the way martial arts are experienced through immersive, blockchain-enabled experiences. In an era characterised by connectivity, immersion and community empowerment, MMA is creating a versatile, dual-layer platform that combines the familiar ...
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
Globenewswire· 2025-06-27 20:00
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. Commenting on the development, Thomas Jensen ...
Calidi Biotherapeutics Announces Shareholder Letter from CEO
Globenewswire· 2025-06-27 20:00
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD. Dear Shareholders, 2025 has been and will continue to be a transformative year for Calidi. We have made substantial changes in the company’s leadership, its ...
Apollo to Announce Second Quarter 2025 Financial Results on August 5, 2025
Globenewswire· 2025-06-27 20:00
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) plans to release financial results for the second quarter 2025 on Tuesday, August 5, 2025, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am EDT via public webcast available on Apollo’s Investor Relations website at ir.apollo.com. A replay will be available one hour after the event. Apollo distributes its earnings releases via its website and email lists. Those interested i ...
Locafy Partners with Leading U.S. Reputation Platform - Plans to Scale Deployment of “AI-Ready” Search Solutions
Globenewswire· 2025-06-27 20:00
Agreement Expands U.S. Business Listing Syndication by Approximately 10,000 End Users Locafy’s “AI Search Readiness” Solutions Positioned as Value-Added Upsell to Base Contract PERTH, Australia, June 27, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (NASDAQ: LCFY, “Locafy” or the “Company”), a globally recognized leader in location-based digital marketing, today announced it has entered into a strategic partnership with one of the United States’ foremost online reputation and review management platforms. Under th ...
Abacus Global Management Announces Intention to Conduct Exchange Offer and Consent Solicitation Relating to Warrants
Globenewswire· 2025-06-27 20:00
ORLANDO, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (the “Company”) (NASDAQ: ABL), today announced that it intends to conduct an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants to purchase shares of common stock of the Company, par value $0.0001 per share (“common stock”), which warrants trade on The Nasdaq Capital Market under the symbol “ABLLW” (“public warrants”), and (ii) private placement warr ...
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
Globenewswire· 2025-06-27 20:00
Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...
AYR Wellness Provides Update on Q1 2025 Interim Filings
Globenewswire· 2025-06-27 20:00
MIAMI, June 27, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, provides an update regarding the status of its interim financial statements, management’s discussion and analysis, and related CEO and CFO certificates for the three-month period ended March 31, 2025 (collectively, the “Interim Filings”). As previously disclosed, the Company’s delay in completing the Interim Filings is primarily ...
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Globenewswire· 2025-06-27 20:00
GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellul ...